Amine oxidases in bovine serum generate products that are cytotoxic and mutagenic to cultured human and murine cells. Short-term toxicity of these byproducts is seen as a lack of survival of hematopoietic progenitor cells, associated with low cloning efficiencies. Long-term toxicity is seen as in vitro evolution of primary cultures of mouse embryo cells, leading to """"""""immortalization."""""""" Therefore, during the Phase I Grant, we studied the feasibility of purifying the amine oxidases in bovine serum, in order to generate amine oxidase-depleted bovine serum. The Phase II application will involve generating amine oxidase-free bovine serum by elimination of enzyme activity. This serum will be tested in various short-term and long-term blood cell cultures.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44CA057118-02
Application #
2097854
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1992-07-01
Project End
1996-02-28
Budget Start
1994-03-04
Budget End
1995-02-28
Support Year
2
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Hipple Cancer Research Corporation
Department
Type
DUNS #
City
Dayton
State
OH
Country
United States
Zip Code
45439